A genetic heart condition caused by mutations in the KCNH2 gene, often leading to abnormal heart rhythms

What is KCNH2-Linked Cardiac Disease?

KCNH2-linked cardiac disease is a type of genetic heart condition caused by mutations in the KCNH2 gene, which encodes a potassium ion channel critical for regulating the heart’s electrical activity. This disorder is most commonly associated with Long QT Syndrome Type 2 (LQT2), a condition that can lead to dangerous arrhythmias, fainting, and sudden cardiac death if not properly managed.

The KCNH2 gene is also known as HERG (human ether-à-go-go-related gene), and its dysfunction affects the repolarization phase of the heart’s electrical cycle.

What causes KCNH2-Linked Cardiac Disease?

This condition is caused by genetic mutations in the KCNH2 gene. These mutations disrupt the function of the potassium channels in the heart, which are essential for resetting the heart’s electrical rhythm between beats.

The result is a prolonged QT interval on the electrocardiogram (ECG), making the heart more susceptible to torsades de pointes, a type of life-threatening arrhythmia.

Who is at risk?

• Individuals with a family history of Long QT Syndrome or sudden cardiac death
• Those who inherit a mutated copy of the KCNH2 gene (autosomal dominant inheritance)
• Women, who are often more sensitive to the effects of QT prolongation
• People exposed to QT-prolonging medications or who have electrolyte imbalances
• Individuals with undiagnosed congenital KCNH2 mutations

What are the symptoms of KCNH2-Linked Cardiac Disease?

Symptoms can vary widely in severity and may include:

• Palpitations (fluttering or racing heartbeats)
• Fainting spells (syncope), especially during stress, emotion, or exercise
• Seizure-like episodes (due to reduced blood flow to the brain)
• Sudden cardiac arrest (in severe, untreated cases)
• Some individuals may be asymptomatic but still at risk

How is KCNH2-Linked Cardiac Disease diagnosed?

Diagnosis is made through a combination of clinical evaluation and genetic testing:

• Electrocardiogram (ECG) – to detect QT interval prolongation
• Holter monitor or event recorder – for ongoing heart rhythm monitoring
• Exercise stress test – to observe how the heart behaves under stress
• Genetic testing – to identify mutations in the KCNH2 gene
• Family screening – to detect undiagnosed cases among relatives

How is KCNH2-Linked Cardiac Disease treated?

Treatment is aimed at preventing arrhythmias and sudden death:

• Beta-blockers – commonly used to reduce the risk of arrhythmias
• Avoidance of QT-prolonging medications (e.g., certain antibiotics, antihistamines, or antidepressants)
• Lifestyle modifications – avoiding intense physical exertion, emotional stress, and startling situations
• Implantable cardioverter-defibrillator (ICD) – for patients at high risk or with a history of cardiac arrest
• Left cardiac sympathetic denervation (LCSD) – in selected severe cases
• Genetic counseling for patients and families

What is the prognosis for KCNH2-Linked Cardiac Disease?

• With early diagnosis and proper management, many individuals live healthy, normal lives
• Undiagnosed or untreated cases can lead to sudden death, especially in young individuals
• Ongoing monitoring and medication adherence are key to long-term safety
• Family members of affected individuals should also undergo evaluation and screening

Can KCNH2-Linked Cardiac Disease be prevented?

It cannot be prevented entirely because it is genetic, but early detection and management can prevent complications:

• Routine ECGs and genetic screening in families with a history of Long QT Syndrome
• Avoiding known triggers, such as certain medications or electrolyte imbalances
• Medical alert identification and emergency plans for at-risk individuals
• Education of family and caregivers about recognizing and responding to symptoms